Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries.
Giacomo Bellani, John G Laffey, Tài Pham...
https://pubmed.ncbi.nlm.nih.gov/26903337/Actively Recruiting
Led by Università Vita-Salute San Raffaele · Updated on 2026-05-08
130
Participants Needed
17
Research Sites
26 weeks
Total Duration
Acute respiratory distress syndrome ARDS is a serious lung condition causing inflammation and fluid buildup, leading to severe breathing problems and high mortality in intensive care units worldwide. Despite many clinical trials, no specific drug has yet proven effective in treating ARDS. The study aims to evaluate the anti-fibrotic medication Pirfenidone, previously used for idiopathic pulmonary fibrosis, to see if it can prevent lung fibrosis and improve outcomes in ARDS patients. Participants will be randomly assigned to receive either Pirfenidone or a placebo. Pirfenidone dosing starts at 801 mg per day for the first week, increases to 1602 mg per day for the second week, and then to 2403 mg per day until ICU discharge. The medication or placebo is given through a nasogastric tube in three divided doses daily. This is a phase 3 randomized controlled trial conducted across multiple centers. Throughout the study, researchers will monitor the number of days participants are free from ventilators within 28 days, length of ICU stay, lung imaging changes, mortality rates, lung function tests, heart function, and quality of life up to one year. Samples from the lungs will also be collected to study inflammation. Safety and any adverse effects will be closely tracked. The study will continue until December 2026.
CONDITIONS
Pirfenidone to Prevent Fibrosis in Ards.
N
Nora Di Tomasso, MD
G
Giacomo Monti, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Università Vita-Salute San Raffaele
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to ICU discharge
Participants receive either Pirfenidone or placebo delivered by a nasogastric tube in 3 daily doses. The dosing is 801 mg/day from days 1 to 7, 1602 mg/day from days 8 to 14, and 2403 mg/day from day 15 until ICU discharge.
Daily dosing with clinical monitoring during ICU stay
Duration - Up to 12 months after treatment
Participants undergo quality of life assessments and lung function tests for up to 12 months after treatment completion to monitor longer-term outcomes.
Follow-up visits at 6 and 12 months
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Giacomo Bellani, John G Laffey, Tài Pham...
https://pubmed.ncbi.nlm.nih.gov/26903337/Joan R Masclans, Oriol Roca, Xavier Muñoz...
https://pubmed.ncbi.nlm.nih.gov/21330382/Chen Yu Wang, Carolyn S Calfee, Devon W Paul...
https://pubmed.ncbi.nlm.nih.gov/24435201/Ashish Agrawal, Hanjing Zhuo, Sandra Brady...
https://pubmed.ncbi.nlm.nih.gov/22865551/V B Lindén, M K Lidegran, G Frisén...
https://pubmed.ncbi.nlm.nih.gov/19226296/Kentaro Iwata, Asako Doi, Goh Ohji...
https://pubmed.ncbi.nlm.nih.gov/21088343/Lieuwe D Bos, Ignacio Martin-Loeches, Marcus J Schultz
https://pubmed.ncbi.nlm.nih.gov/29367411/C Martin, L Papazian, M J Payan...
https://pubmed.ncbi.nlm.nih.gov/7813276/Acute Respiratory Distress Syndrome Network, Roy G Brower, Michael A Matthay...
https://pubmed.ncbi.nlm.nih.gov/10793162/Giacomo Monti, Matteo Marzaroli, Maria Teresa Tucciariello...
https://pubmed.ncbi.nlm.nih.gov/40090666/Università Vita-Salute San Raffaele
Lead Sponsor